6 unchanged sentences
Name Age Position
−Removed: Gonzalez 71 Executive Chairman of the Board and Retired Chief Executive Officer
−Removed: Michael 54 Chief Executive Officer
+Added: Michael 55 Chairman of the Board and Chief Executive Officer
Reents 58 Executive Vice President, Chief Financial Officer
+Added: Crum 45 Executive Vice President, Chief Human Resources Officer
Donoghoe, M.D.
45 Executive Vice President, Chief Business and Strategy Officer
−Removed: Richmond 58 Executive Vice President, Chief Human Resources Officer
Azita Saleki-Gerhardt, Ph.D.
4 unchanged sentences
54 Executive Vice President, Research & Development and Chief Scientific Officer
−Removed: Buckbee 59 Senior Vice President, Controller
+Added: Purdue 48 Senior Vice President, Controller
_______________________________________________________________________________
−Removed: Gonzalez is the Executive Chairman of the Board.
−Removed: Gonzalez served as Chairman and Chief Executive Officer of AbbVie from 2013 to June 2024.
−Removed: He served as Abbott’s Executive Vice President of the pharmaceutical products group from July 2010 to December 2012, and was responsible for Abbott’s worldwide pharmaceutical business, including commercial operations, research and development, and manufacturing.
−Removed: He also served as President, Abbott Ventures Inc., Abbott’s medical technology investment arm, from 2009 to 2011.
−Removed: Gonzalez joined Abbott in 1977 and held various management positions before briefly retiring in 2007, including:
−Removed: Abbott’s President and Chief Operating Officer; President, Chief Operating Officer of Abbott’s Medical Products Group; Senior Vice President and President of Abbott’s former Hospital Products Division; Vice President and President of Abbott’s Health Systems Division; and Divisional Vice President and General Manager for Abbott’s Diagnostics Operations in the United States and Canada.
−Removed: On February 13, 2025, the Board of Directors of AbbVie unanimously elected Mr.
−Removed: Michael to succeed Mr.
−Removed: Gonzalez as Chairman of the Board of Directors, effective July 1, 2025, at which time Mr.
−Removed: Gonzalez will retire from the Board.
−Removed: Michael is AbbVie’s Chief Executive Officer, a position he has held since July 2024, and serves on its Board of Directors.
−Removed: Michael previously served as President and Chief Operating Officer from July 2023 to June 2024, as Vice Chairman and President from June 2022 to July 2023, as Vice Chairman, Finance and Commercial Operations and Chief Financial Officer from June 2021 to June 2022, as Executive Vice President, Chief Financial Officer from 2019 to 2021, as Senior Vice President, Chief Financial Officer from 2018 to 2019 and as Vice President, Controller from 2017 to 2018.
+Added: Michael is AbbVie’s Chairman and Chief Executive Officer, a position he has held since July 2025.
+Added: Michael previously served as Chief Executive Officer starting in 2024 and President and Chief Operating Officer from July 2023 to June 2024, as Vice Chairman and President from June 2022 to July 2023, as Vice Chairman, Finance and Commercial Operations and Chief Financial Officer from June 2021 to June 2022, as Executive Vice President, Chief Financial Officer from 2019 to 2021, as Senior Vice President, Chief Financial Officer from 2018 to 2019 and as Vice President, Controller from 2017 to 2018.
He served as AbbVie's Vice President, Treasurer from 2015 to 2016, as Vice President, Controller, Commercial Operations from 2013 to 2015 and as Vice President, Financial Planning and Analysis from 2012 to 2013.
2 unchanged sentences
Michael joined Abbott in 1993 and was first appointed as an AbbVie corporate officer in March 2017.
−Removed: On February 13, 2025, the Board of Directors of AbbVie unanimously elected Mr.
−Removed: Michael to succeed Mr.
−Removed: Gonzalez as Chairman of the Board of Directors, effective July 1, 2025, at which time Mr.
−Removed: Gonzalez will retire from the Board.
Reents is AbbVie’s Executive Vice President, Chief Financial Officer.
1 unchanged sentence
Reents joined Abbott in 2008 and was first appointed as an AbbVie corporate officer in June 2022.
+Added: Crum is AbbVie’s Executive Vice President, Chief Human Resources Officer.
+Added: He previously served as Vice President, Total Rewards from August 2022 to June 2025, as Vice President, Compensation from January 2022 to August 2022, and as Vice President, Business Human Resources for corporate staff functions from August 2020 to January 2022.
+Added: Crum joined AbbVie in 2017 and was first appointed as an AbbVie corporate officer in July 2025.
+Added: Prior to joining AbbVie, Mr.
+Added: Crum held several human resources leadership roles at The Kraft Heinz Company and PepsiCo.
Donoghoe is AbbVie’s Executive Vice President, Chief Business and Strategy Officer.
−Removed: He has previously served as AbbVie’s Senior Vice President, Chief Operating Officer, R&D from 2022 to 2023, as Senior Vice President, Portfolio Innovation from 2021 to 2022, as Senior Vice President, Global Strategy and Operations, Allergan Aesthetics, from 2020 to 2021, and as Senior Vice President, Enterprise Innovation from 2019 to 2020.
−Removed: Prior to joining AbbVie in 2019, he served as a Partner at McKinsey & Company where he was a leader of the firm's Pharma and Biotechnology practice for over a decade.
−Removed: Richmond is AbbVie’s Executive Vice President, Chief Human Resources Officer.
−Removed: He served as Senior Vice President, Human Resources from 2013 to 2018.
−Removed: Richmond served as Abbott’s Divisional Vice President of Compensation & Benefits from 2008 to 2012, as Group Vice President of Talent and Rewards from 2007 to 2008 and as Divisional Vice President of Talent Acquisition from 2006 to 2007.
−Removed: Richmond joined Abbott in 2006 and was first appointed as an AbbVie corporate officer in December 2012.
−Removed: 2024 Form 10-K |
+Added: He previously served as AbbVie’s Senior Vice President, Chief Operating Officer, R&D from 2022 to 2023, as Senior Vice President, Portfolio Innovation from 2021 to 2022, as Senior Vice President, Global Strategy and Operations, Allergan Aesthetics, from 2020 to 2021, and as Senior Vice President, Enterprise Innovation from 2019 to 2020.
+Added: Donoghoe was first appointed as an AbbVie corporate officer in January 2019 when he joined AbbVie.
+Added: Prior to joining AbbVie, he served as a Partner at McKinsey & Company where he was a leader of the firm's Pharma and Biotechnology practice for over a decade.
Saleki-Gerhardt is AbbVie’s Executive Vice President, Chief Operations Officer.
−Removed: She served as Executive Vice President, Operations from 2018 to July 2023, and as Senior Vice President, Operations from 2013 to 2018.
+Added: She previously served as Executive Vice President, Operations from 2018 to July 2023, and as Senior Vice President, Operations from 2013 to 2018.
Saleki-Gerhardt served as Abbott’s Vice President, Pharmaceuticals Manufacturing and Supply from 2011 to 2012, and as Divisional Vice President, Quality Assurance, Global Pharmaceutical Operations from 2008 to 2011.
2 unchanged sentences
Siatis is AbbVie’s Executive Vice President, General Counsel and Secretary.
−Removed: Siatis previously served as Senior Vice President, Deputy General Counsel from September 2021 until October 2022.
+Added: He previously served as Senior Vice President, Deputy General Counsel from September 2021 until October 2022.
From 2013 until 2021, Mr.
−Removed: Siatis also served in various roles including as Senior Vice President, Legal and Chief Ethics and Compliance Officer; Senior Vice President of Legal Transactions and R&D/Alliance Management and Chief Ethics and Compliance Officer; and Vice President, Biologic Strategic Development and Legal Regulatory.
+Added: Siatis also served in various roles including as Senior Vice President, Legal and Chief Ethics and Compliance Officer, as Senior Vice President of Legal Transactions and R&D/Alliance Management and Chief Ethics and Compliance Officer, and as Vice President, Biologic Strategic Development and Legal Regulatory.
Siatis joined Abbott in 2005 and was first appointed as an AbbVie corporate officer in October 2022.
1 unchanged sentence
He previously served as Senior Vice President, U.S.
−Removed: Commercial Operations from 2018 to 2020 and as AbbVie’s President, Commercial Operations from 2013 to 2018.
+Added: Commercial Operations from 2018 to 2020 and as AbbVie’s President, U.S.
+Added: Commercial Operations from 2013
+Added: 2025 Form 10-K |
Prior to AbbVie’s separation from Abbott, he served as Vice President, Abbott Proprietary Pharmaceutical Division, United States.
2 unchanged sentences
He previously served as Senior Vice President of Development and Regulatory Affairs and Chief Medical Officer at AbbVie from 2022 until 2023, as Vice President, Global Regulatory Affairs and R&D Quality Assurance from 2019 to 2022, and as Vice President, Global Regulatory Affairs from 2015 to 2019.
−Removed: Thakkar joined Abbott in 2003 and was first appointed as a corporate officer in December 2023.
−Removed: Buckbee is AbbVie’s Senior Vice President, Controller.
−Removed: Buckbee previously served as AbbVie’s Vice President, Controller, Global Commercial Operations from January 2016 until March 2023, and as Vice President, Controller, U.S.
−Removed: Commercial Operations from AbbVie’s separation from Abbott in 2013 until December 2015.
−Removed: Buckbee joined Abbott in 1991 and held several positions in the finance organization.
+Added: Thakkar joined Abbott in 2003 and was first appointed as an AbbVie corporate officer in December 2023.
+Added: Purdue is AbbVie’s Senior Vice President, Controller.
+Added: He previously served as AbbVie’s Vice President, Controller, Commercial Operations from 2023 to 2025, Vice President, Corporate Treasurer from 2022 to 2023, Vice President, Corporate Financial Planning and Analysis from 2020 to 2022, and Vice President, Allergan Integration from 2019 to 2020.
+Added: Purdue joined Abbott in 2003 and was first appointed as an AbbVie corporate officer in March 2025.
The executive officers of AbbVie are elected annually by the board of directors.
5 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.